CGCarlos A. Garcia-Prieto

Carlos A. Garcia-Prieto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carlos A. Garcia-Prieto has a total of 181 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Spatial transcriptomics unveils the in situ cellular and molecular hallmarks of the lung in fatal COVID-19

    by Carlos A. Garcia-Prieto, Eva Musulen, Daniela Grases, Veronica Davalos, Gerardo Ferrer, Belén Pérez-Miés, Tamara Caniego-Casas, José Palacios, Xavier Saenz-Sardà, Elisabet Englund, et al.

    Severe Coronavirus disease 2019 (COVID-19) can induce progressive diffuse alveolar damage (DAD) leading to fatal outcomes. Here, we leveraged data from Visium spatial transcriptomics for COVID-19 and control lung samples to unravel insights into cellular and molecular events driving lethal COVID-19. We report a progressive loss of endothelial cell types, pneumocytes type I and natural killer cells coupled with a continuous increase of myeloid and stromal cells, mostly peribronchial fibroblasts, across acute and proliferative DAD. Spatial organization analysis also identified specific compartmentalization including immune-specific clusters across DAD patterns. Importantly, spatially informed ligand-receptor interaction analysis revealed intercellular communication signatures defining COVID-19 induced DAD. Transcription factor activity enrichment analysis identified the TGF-β pathway as DAD driver, highlighting the antagonizing roles of SMAD3 and SMAD7 activity during fibrosis. Integration of these data yielded a signaling kinase pathway in peribronchial fibroblasts with amenable novel targets. Finally, spatio-temporal trajectory analysis characterized an alveolar epithelium regeneration program.

  • Open Access

    Supplementary Figures from DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features

    by Nicole Thomas, Carlos A. García-Prieto, Kostiantyn Dreval, Laura K. Hilton, Jeremy S. Abramson, Nancy L. Bartlett, Jeffrey Bethony, Jay Bowen, Anthony C. Bryan, Corey Casper, et al.

    Supplemental Figure 1. Association between genetic alterations and methylation patterns Supplemental Figure 2. Epitypes characteristics and their relation to other lymphomas. Supplemental Figure 3. Comparison of epitype characteristics in relation to EBV status. Supplemental Figure 4. Validation of epitypes using Nanopore sequencing data. Supplemental Figure 5. Selected characteristics of BL epitypes and relative aSHM frequencies in EBV-positive BL. Supplemental Figure 6. GSEA plots for SignatureDB pathways determined to be significantly different between BL epitypes. Supplemental Figure 7. The Cox proportional hazards models accounting for both BL epitype and TP53 mutation status in adult BLs.

  • Open Access

    Supplementary Tables from DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features

    by Nicole Thomas, Carlos A. García-Prieto, Kostiantyn Dreval, Laura K. Hilton, Jeremy S. Abramson, Nancy L. Bartlett, Jeffrey Bethony, Jay Bowen, Anthony C. Bryan, Corey Casper, et al.

    S1. DMRs EBVpos vs CB S2. DMRs EBVneg vs CB S3. Shared DMRs EBV S4. DMRs EBV status S5. Methylation gene corrs EB S6. GO pathways enrichment S7. LPS selected probes S8. Epitype assignment S9. DMRs eptiype S10. DMR gene corrs epitype S11. JASPAR TF results epitype S12. JASPAR TF results EBV S13. aSHM epitype S14. DEG epitpye S15. SignatureDB pathways enrichment

  • Open Access

    DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features

    by Nicole Thomas, Carlos A. García-Prieto, Kostiantyn Dreval, Laura K. Hilton, Jeremy S. Abramson, Nancy L. Bartlett, Jeffrey Bethony, Jay Bowen, Anthony C. Bryan, Corey Casper, et al.

    The genetic subtypes of Burkitt lymphoma have been defined, but the role of epigenetics remains to be comprehensively characterized. We searched genomic DNA from 218 patients across four continents for recurrent DNA methylation patterns and their associations with clinical and molecular features. We identified DNA methylation patterns that were not fully explained by the Epstein–Barr virus status or mutation status, leading to two epitypes described here as HypoBL and HyperBL. Each is characterized by distinct genomic and clinical features including global methylation, mutation burden, aberrant somatic hypermutation, and survival outcomes. Methylation, gene expression, and mutational differences between the epitypes support a model in which each arises from a distinct cell of origin. These results, pending validation in external cohorts, point to a refined risk assessment for patients with Burkitt lymphoma who may experience inferior outcomes. Significance: Burkitt lymphoma can be divided into two epigenetic subtypes (epitypes), each carrying distinct biological, transcriptomic, genomic, and clinical features. Epitype is more strongly associated with clinical and mutational features than the Epstein–Barr virus status or genetic subtype, highlighting an important additional layer of Burkitt lymphoma pathogenesis.


  • Open Access

    A DNA methylation database of human and mouse hematological malignancy cell lines

    by Aleix Noguera-Castells, Carlos A. García-Prieto, Gerardo Ferrer, Veronica Davalos, Fernando Setien, Eulàlia Genescà, Jordi Ribera, Josep M. Ribera, Manel Esteller


  • Open Access

    PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

    by Laura Martinez-Verbo, Yoana Veselinova, Pere Llinàs-Arias, Carlos A. García-Prieto, Aleix Noguera-Castells, Miguel L. Pato, Alberto Bueno-Costa, Ignacio Campillo-Marcos, Lorea Villanueva, Aina Oliver-Caldes, et al.


  • Open Access

    The scaffolding function of LSD1 controls DNA methylation in mouse ESCs

    by Sandhya Malla, Kanchan Kumari, Carlos A. García-Prieto, Jonatan Caroli, Anna Nordin, Trinh T. T. Phan, Devi Prasad Bhattarai, Carlos Martinez-Gamero, Eshagh Dorafshan, Stephanie Stransky, et al.

    Lysine-specific histone demethylase 1 (LSD1), which demethylates mono- or di- methylated histone H3 on lysine 4 (H3K4me1/2), is essential for early embryogenesis and development. Here we show that LSD1 is dispensable for mouse embryonic stem cell (ESC) self-renewal but is required for mouse ESC growth and differentiation. Reintroduction of a catalytically-impaired LSD1 (LSD1MUT) recovers the proliferation capability of mouse ESCs, yet the enzymatic activity of LSD1 is essential to ensure proper differentiation. Indeed, increased H3K4me1 in Lsd1 knockout (KO) mouse ESCs does not lead to major changes in global gene expression programs related to stemness. However, ablation of LSD1 but not LSD1MUT results in decreased DNMT1 and UHRF1 proteins coupled to global hypomethylation. We show that both LSD1 and LSD1MUT control protein stability of UHRF1 and DNMT1 through interaction with HDAC1 and the ubiquitin-specific peptidase 7 (USP7), consequently, facilitating the deacetylation and deubiquitination of DNMT1 and UHRF1. Our studies elucidate a mechanism by which LSD1 controls DNA methylation in mouse ESCs, independently of its lysine demethylase activity.


  • Open Access

    The scaffolding function of LSD1 controls DNA methylation in mouse ESCs

    by Sandhya Malla, Kanchan Kumari, Carlos A. García-Prieto, Jonatan Caroli, Anna Nordin, Trinh T. T. Phan, Devi Prasad Bhattarai, Carlos Martinez-Gamero, Eshagh Dorafshan, Stephanie Stransky, et al.

    Lysine-specific histone demethylase 1 (LSD1), which demethylates mono- or di- methylated histone H3 on lysine 4 (H3K4me1/2), is essential for early embryogenesis and development. Here we show that LSD1 is dispensable for mouse embryonic stem cell (ESC) self-renewal but is required for mouse ESC growth and differentiation. Reintroduction of a catalytically-impaired LSD1 (LSD1MUT) recovers the proliferation capability of mouse ESCs, yet the enzymatic activity of LSD1 is essential to ensure proper differentiation. Indeed, increased H3K4me1 in Lsd1 knockout (KO) mouse ESCs does not lead to major changes in global gene expression programs related to stemness. However, ablation of LSD1 but not LSD1MUT results in decreased DNMT1 and UHRF1 proteins coupled to global hypomethylation. We show that both LSD1 and LSD1MUT control protein stability of UHRF1 and DNMT1 through interaction with HDAC1 and the ubiquitin-specific peptidase 7 (USP7), consequently, facilitating the deacetylation and deubiquitination of DNMT1 and UHRF1. Our studies elucidate a mechanism by which LSD1 controls DNA methylation in mouse ESCs, independently of its lysine demethylase activity.

  • Open Access

    DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study

    by Aleix Noguera‐Castells, Ignacio Campillo‐Marcos, Veronica Davalos, Carlos A. García‐Prieto, David Valcárcel, Antonieta Molero, Laura Palomo, Norbert Gattermann, Michael Wulfert, Lorea Chaparro‐González, et al.

    Summary: Real‐world data have revealed that a substantial portion of patients with myelodysplastic syndromes (MDS) does not respond to epigenetic therapy with hypomethylating agents (HMAs). The cellular and molecular reasons for this resistance to the demethylating agent and biomarkers that would be able to predict the treatment refractoriness are largely unknown. In this study, we shed light on this enigma by characterizing the epigenomic profiles of patients with MDS treated with azacitidine. Our approach provides a comprehensive view of the evolving DNA methylation architecture of the disease and holds great potential for advancing our understanding of MDS treatment responses to HMAs.


  • Open Access

    Supplementary Information from A Tumor Suppressor Enhancer of PTEN in T-cell Development and Leukemia

    by Luca Tottone, Olga Lancho, Jui-Wan Loh, Amartya Singh, Shunsuke Kimura, Juliette Roels, Anna Kuchmiy, Steven Strubbe, Matthew A. Lawlor, Victoria da Silva-Diz, et al.